Group 1 - Major shareholder Shenzhen Zhongke Investment Co., Ltd. held 41,752,818 shares, accounting for 22.2270% of the total share capital before the reduction plan [1][2] - The reduction plan aimed to sell up to 3,756,948 shares, representing 2% of the total share capital, but only 62,000 shares were sold by the deadline [2][4] - The reduction was conducted in compliance with relevant laws and regulations, and the actual reduction met the planned minimum [4] Group 2 - The company will hold a Q3 performance briefing on December 16, 2025, from 10:00 to 11:00 AM, via the Shanghai Stock Exchange Roadshow Center [6][8] - Investors can submit questions from December 9 to December 15, 2025, for discussion during the briefing [11][12] - Key personnel attending the briefing include the CEO and other senior executives [8][10] Group 3 - The National Intellectual Property Administration upheld the validity of the company's patent for a hemostatic clip, which was challenged by Beijing Zhongke Shengkang Technology Co., Ltd. [15][17] - The invalidation request did not negatively impact the company's operations or financial results [16][19] - The company is currently involved in litigation against Zhongke Shengkang for patent infringement, with a previous ruling in its favor [18]

Core Viewpoint - The company, Nanwei Medical Technology Co., Ltd., is currently involved in a patent invalidation request initiated by Beijing Zhongke Shengkang Technology Co., Ltd., which may impact its patent rights and potential compensation from a previous infringement lawsuit [1][2]. Group 1: Case Background - The case is at the stage of acceptance and has not yet been reviewed [1]. - The company is the patent holder involved in the dispute [1]. - The patent in question is for a hemostatic clip (Patent No. 201410222753.7), which was applied for on May 23, 2014, and granted on November 18, 2015 [2]. Group 2: Previous Litigation - The company initiated a patent infringement lawsuit against Zhongke Shengkang, which resulted in a ruling that found Zhongke Shengkang guilty of infringement, ordering them to cease infringing activities and pay the company 700,000 yuan [2]. - Zhongke Shengkang has appealed the first-instance judgment to the Supreme People's Court, and the case is still under review [2]. Group 3: Impact on Company - If the patent is ultimately declared invalid, competitors may use the technology without compensation to the company, affecting the potential recovery from the previous lawsuit [1][3]. - The company asserts that the invalidation of the patent will not significantly impact its production and sales, as it has a robust core technology system that includes multiple patents and technical know-how [4]. - The company reported that its domestic sales of products utilizing the disputed patent were approximately 100 million yuan in 2024 [3].